| 1 |
Cidofovir
47
|
VISTIDE |
US FDA Approved |
Indicated or the treatment of cytomegalovirus retinitis in AIDS patients |
The recommended dose of cidofovir is 5 mg/kg body weight (IV) once weekly. |
Cidofovir suppresses human cytomegalovirus replication by selective inhibition of viral DNA synthesis |
Cidofovir has been shown to be effective against the virus that causes smallpox It is also effective in treating animals that had diseases similar to smallpox It has broad‐spectrum activity against DNA viruses, including herpes‐, adeno‐, polyoma‐, papilloma‐ and poxviruses
|
The safety and efficacy of cidofovir have not been established in patients with hepatic disease, pediatric patients, and geriatric patients. It should be used with lower the risk of blindness and other vision problems. Only IV dosage form is available
|
| 2 |
Brincidofovir
48
|
CMX001/TEMBEXA |
US FDA Approved |
For the treatment of human smallpox disease |
Patients weighing 48 kg or above: 200 mg once weekly for two doses Patients weighing 10 kg to less than 48 kg: 4 mg/kg once weekly for two doses Patients weighing less than 10 kg: 6 mg/kg once weekly for two doses
|
Brincidofovir is an orthopoxvirus nucleotide analog DNA polymerase inhibitor against variola virus |
It can be used in adult and pediatric patients, including neonates It is available as oral suspension and tablets Several animal model studies showed that brincidofovir is effective in monkeypox infection
|
The effectiveness of brincidofovir for treatment of monkeypox infection has not been determined in humans Efficacy may be reduced in immunocompromised patients based on studies in immune deficient animals
|
| 3 |
Tecovirimat
49
|
ST‐246/TPOXX |
US FDA Approved (July 2018) |
Indicated for the treatment of human smallpox disease in adults andpediatric patients weighing at least 13 kg |
Patients weighing 40 kg or above: 600 mg twice daily for 14 days Patients weighing 25 kg to less than 40 kg: 400 mg twice daily for 14 days Patients weighing 13 kg to less than 25 kg: 200 mg twice daily for 14 days
|
Tecovirimat is a novel tricyclonene compound that inhibits orthopoxvirus VP37 protein |
It can be used in adult and pediatric patients It is available as oral capsule Several animal and human model studies showed that tecovirimat is effective in monkeypox infection
|
The effectiveness of tecovirimat for treatment of smallpox disease has not been determined in humans by adequate and well‐controlled clinical trials Tecovirimat efficacy may be reduced in immunocompromised patients based on studies in immune deficient animals
|
